Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study

Taro Kishi, Kenji Sakuma, Makoto Okuya, Kohei Ninomiya, Kazuto Oya, Momoko Kubo, Yuki Matsui, Ikuo Nomura, Yuji Okuyama, Shinji Matsunaga, Nakao Iwata

Research output: Contribution to journalArticle

Abstract

Aim: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods: This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. Results: The mean age of the patients was 49.4 ± 17.3 years; 54.4% were women, 49.1% had a major depressive disorder, and 77.2% completed the trial. Compared with the baseline scores (the mean scores for the two days before the start of the study), taking suvorexant was associated with significant improvements in TST, TSO, wake time after sleep onset, and the patients' sleep satisfaction level at week 1. Adverse events included at least one adverse event (43.9%), sleepiness (28.8%), fatigue (11.5%), nightmares (5.8%), headache (3.8%), dizziness (3.8%), and vomiting (1.9%). Conclusion: Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.

Original languageEnglish
Pages (from-to)252-255
Number of pages4
JournalNeuropsychopharmacology reports
Volume39
Issue number3
DOIs
Publication statusPublished - 01-09-2019

Fingerprint

Sleep Initiation and Maintenance Disorders
Psychiatry
Sleep
Safety
Major Depressive Disorder
Dizziness
suvorexant
Patient Satisfaction
Vomiting
Fatigue
Headache
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kishi, Taro ; Sakuma, Kenji ; Okuya, Makoto ; Ninomiya, Kohei ; Oya, Kazuto ; Kubo, Momoko ; Matsui, Yuki ; Nomura, Ikuo ; Okuyama, Yuji ; Matsunaga, Shinji ; Iwata, Nakao. / Suvorexant for insomnia in patients with psychiatric disorder : A 1-week, open-label study. In: Neuropsychopharmacology reports. 2019 ; Vol. 39, No. 3. pp. 252-255.
@article{90ffc6fd46eb4008a36a55d5e4f83b29,
title = "Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study",
abstract = "Aim: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods: This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. Results: The mean age of the patients was 49.4 ± 17.3 years; 54.4{\%} were women, 49.1{\%} had a major depressive disorder, and 77.2{\%} completed the trial. Compared with the baseline scores (the mean scores for the two days before the start of the study), taking suvorexant was associated with significant improvements in TST, TSO, wake time after sleep onset, and the patients' sleep satisfaction level at week 1. Adverse events included at least one adverse event (43.9{\%}), sleepiness (28.8{\%}), fatigue (11.5{\%}), nightmares (5.8{\%}), headache (3.8{\%}), dizziness (3.8{\%}), and vomiting (1.9{\%}). Conclusion: Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.",
author = "Taro Kishi and Kenji Sakuma and Makoto Okuya and Kohei Ninomiya and Kazuto Oya and Momoko Kubo and Yuki Matsui and Ikuo Nomura and Yuji Okuyama and Shinji Matsunaga and Nakao Iwata",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/npr2.12069",
language = "English",
volume = "39",
pages = "252--255",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Kishi, T, Sakuma, K, Okuya, M, Ninomiya, K, Oya, K, Kubo, M, Matsui, Y, Nomura, I, Okuyama, Y, Matsunaga, S & Iwata, N 2019, 'Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study', Neuropsychopharmacology reports, vol. 39, no. 3, pp. 252-255. https://doi.org/10.1002/npr2.12069

Suvorexant for insomnia in patients with psychiatric disorder : A 1-week, open-label study. / Kishi, Taro; Sakuma, Kenji; Okuya, Makoto; Ninomiya, Kohei; Oya, Kazuto; Kubo, Momoko; Matsui, Yuki; Nomura, Ikuo; Okuyama, Yuji; Matsunaga, Shinji; Iwata, Nakao.

In: Neuropsychopharmacology reports, Vol. 39, No. 3, 01.09.2019, p. 252-255.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suvorexant for insomnia in patients with psychiatric disorder

T2 - A 1-week, open-label study

AU - Kishi, Taro

AU - Sakuma, Kenji

AU - Okuya, Makoto

AU - Ninomiya, Kohei

AU - Oya, Kazuto

AU - Kubo, Momoko

AU - Matsui, Yuki

AU - Nomura, Ikuo

AU - Okuyama, Yuji

AU - Matsunaga, Shinji

AU - Iwata, Nakao

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Aim: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods: This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. Results: The mean age of the patients was 49.4 ± 17.3 years; 54.4% were women, 49.1% had a major depressive disorder, and 77.2% completed the trial. Compared with the baseline scores (the mean scores for the two days before the start of the study), taking suvorexant was associated with significant improvements in TST, TSO, wake time after sleep onset, and the patients' sleep satisfaction level at week 1. Adverse events included at least one adverse event (43.9%), sleepiness (28.8%), fatigue (11.5%), nightmares (5.8%), headache (3.8%), dizziness (3.8%), and vomiting (1.9%). Conclusion: Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.

AB - Aim: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. Methods: This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. Results: The mean age of the patients was 49.4 ± 17.3 years; 54.4% were women, 49.1% had a major depressive disorder, and 77.2% completed the trial. Compared with the baseline scores (the mean scores for the two days before the start of the study), taking suvorexant was associated with significant improvements in TST, TSO, wake time after sleep onset, and the patients' sleep satisfaction level at week 1. Adverse events included at least one adverse event (43.9%), sleepiness (28.8%), fatigue (11.5%), nightmares (5.8%), headache (3.8%), dizziness (3.8%), and vomiting (1.9%). Conclusion: Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. However, this study was of short duration and included only a relatively small number of patients. A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=85071783236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071783236&partnerID=8YFLogxK

U2 - 10.1002/npr2.12069

DO - 10.1002/npr2.12069

M3 - Article

C2 - 31283862

AN - SCOPUS:85071783236

VL - 39

SP - 252

EP - 255

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

IS - 3

ER -